Navigation Links
Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
Date:7/16/2008

port approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
2. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
3. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
6. MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
7. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
8. Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
9. Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
10. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
11. Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014  Perrigo Company (NYSE: PRGO ; ... therapeutic equivalent rating from the U.S. Food and Drug ... (NDA) for testosterone gel 1.0%. FDA concluded that Perrigo,s ... and can be substituted with the full expectation that ... profile as AndroGel 1% when used under the conditions ...
(Date:7/24/2014)... , July 24, 2014 Research ... "Machine Health Monitoring Market by Product, Component, Application and ... report to their offering. ... market is expected to witness a moderate growth as ... have almost reached the saturation levels. The ...
(Date:7/24/2014)... 24, 2014 /PRNewswire-iReach/ -- Delivery of the Report ... placed. Photo - http://photos.prnewswire.com/prnh/20140723/129707 ... in-depth market survey on Global and Chinese Hemodialysis ... information of Hemodialysis Machine including its classification, application ... and China,s top manufacturers of Hemodialysis Machine listing ...
Breaking Medicine Technology:Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3Machine Health Monitoring (Vibration Monitoring, Thermography, Ultrasound Emission, Lubricating Oil Analysis, Corrosion Monitoring, Motor Current Signature Analysis) Market - Forecast to 2020 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 5
... patients can drive safely six weeks following surgical,treatment, ... most patients, pain levels are so low that they ... car again. A study published in the August,2008 issue ... http://www.jbjs.org/ ),also found that emergency brake time response in ...
... Calif., Aug. 26 XTENT, Inc.,(Nasdaq: XTNT ) ... CUSTOM II trial was published in the most recent ... the article was,Dr. Pieter R. Stella, M.D., of University ... CUSTOM II Investigators from 13 clinical,sites across Europe., ...
Cached Medicine Technology:Braking After Bunion Surgery 2Braking After Bunion Surgery 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 2XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 4
(Date:7/24/2014)... Tenn. Researchers at Le Bonheur Children,s Hospital and ... of a clinical trial of a new drug shown ... of healthy adult volunteers intranasally infected with respiratory syncytial ... lower respiratory tract infections in young children in the ... from the labs of Infectious Disease Specialist John DeVincenzo, ...
(Date:7/24/2014)... In signing the Workforce Innovation ... the Atlanta BeltLine Workforce Partnership in Healthcare as ... country ( http://www.whitehouse.gov/ready-to-work ). The Administration called ... U.S. economic strategy and profiled successful local efforts ... President Obama highlights the power of partnerships in ...
(Date:7/24/2014)... scientists at Carnegie Mellon University, working with high-throughput ... Berkeley National Laboratory, have devised a computational method ... normal breast cells turn malignant and as they ... for analyzing how genes interact with each other ... published today by the online journal PLOS ...
(Date:7/24/2014)... rare procedure occasionally performed during Jewish circumcisions that involves ... herpes simplex virus type 1 (HSV-1) transmissions documented in ... conducted by Penn Medicine researchers and published online ... Society found. The reviewers, from Penn,s ... in New York, Canada and Israel. , The practiceknown ...
(Date:7/24/2014)... PROVIDENCE, R.I. Lynn E. Taylor, M.D., director ... states in the July, 2014 Rhode Island ... C" that eliminating hepatitis c virus infection (hep ... benefits, enhance capacity to address other health challenges, ... HCV in the United States, Taylor says, include ...
Breaking Medicine News(10 mins):Health News:RSV research breakthrough to help infected children 2Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 2Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 3Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 4Health News:President Cites Atlanta BeltLine Workforce Partnership in Healthcare as National Model 5Health News:Gene changes in breast cancer cells pinpointed with new computational method 2Health News:Gene changes in breast cancer cells pinpointed with new computational method 3Health News:Link between ritual circumcision procedure and herpes infection in infants examined 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 3Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 4
... POTOMAC FALLS, Va., Nov. 3 "When my father ... read every book,pamphlet, and newspaper article I could get ... book, "A Conversation About Alzheimer,s" (published by,AuthorHouse -- ... think about. I told myself that once I knew ...
... more common for adolescents illegally at the wheel, study finds, ... the thought of teenagers driving before they,ve gotten their license ... are also more likely to drive while drinking or on ... get behind the wheel. , Reporting in the November issue ...
... JOHNSON,S(R) Partners With MARCH OF DIMES(R) To Build ... The United States, SKILLMAN, N.J., Nov. 3 ... of "Prematurity Awareness Month" that partners,with the March ... growing problem of,premature birth and raise funds to ...
... 3 /Xinhua-PRNewswire-FirstCall/ -- China-Biotics,Inc. (Nasdaq: CHBT ) ... the research, development, manufacture, marketing and,distribution of probiotics ... call at 9:00 a.m. EST on Tuesday, November ... the second quarter ended,September 30, 2008, of its ...
... Nov. 3 Hooper Holmes,(Amex: HH ) today ... before market on Friday, November 7, 2008. The Company,will ... at 11:00am Eastern,Time., Conference Call, To participate ... code: Hooper Holmes. A live web cast will be ...
... Inc. (Nasdaq: MBRK ), a pharmaceutical ... products, today,announced that it has retained national ... will serve as MiddleBrook,s strategic and tactical ... reimbursement, contract,administration, national account management and government ...
Cached Medicine News:Health News:'A Conversation About Alzheimer's': Woman Shares Story of Love, Hope, Loss and Survival in New Book About Alzheimer's Disease 2Health News:Many Unlicensed Teen Drivers Put Safety Last 2Health News:Many Unlicensed Teen Drivers Put Safety Last 3Health News:JOHNSON'S(R) and March of Dimes(R) Launch 'Prevent Prematurity Campaign' 2Health News:JOHNSON'S(R) and March of Dimes(R) Launch 'Prevent Prematurity Campaign' 3Health News:China-Biotics, Inc. Announces Conference Call to Discuss Second Quarter 2009 Financial Results 2Health News:China-Biotics, Inc. Announces Conference Call to Discuss Second Quarter 2009 Financial Results 3Health News:Hooper Holmes Announces Third Quarter Earnings Release Date and Conference Call Information 2Health News:MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates 2Health News:MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates 3
Lyphochek Hemoglobin A2 Control is a human whole blood based product designed to monitor the performance of automated and manual procedures for the measurement of hemoglobin variants, including Hemog...
... Liquichek Hematology-16 Control ... use on most hematology ... to 16 parameters and ... differentials. This trilevel control ...
Liquichek Hematology Control (C) is an assayed hematology control for evaluating the performance of Coulter hematology instruments with complete CBC and VCS 5-part differential technology....
... Amplichek CT/GC Controls are liquid ... precision of test procedures that ... gonorrhoeae. Since they are specimen ... with either urine or endocervical/urethral ...
Medicine Products: